Piramal Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 14, 2025, recommended Final Dividend of 0.14 per equity share.
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.0 pts less than Nifty Smallcap 250 and 5.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Piramal Pharma's Board recommended a final dividend of Rs. 0.14 per equity share (face value Rs. 10) for FY25, subject to shareholder approval at the AGM. The Board also approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025. On a consolidated basis, revenue from operations grew to Rs. 9,151.18 crores from Rs. 8,171.16 crores in FY24, while net profit jumped sharply to Rs. 91.13 crores from Rs. 17.82 crores. Standalone net profit rose to Rs. 691.40 crores from Rs. 391.22 crores, with standalone EPS of Rs. 5.22 versus Rs. 3.05. Additionally, Mr. Neeraj Bharadwaj resigned as Non-Executive, Non-Independent Director (Carlyle representative) due to personal commitments, and Mr. Amit Jain was appointed in his place.
The dividend is very small (Rs. 0.14 per share), offering minimal income for shareholders. However, the strong jump in both standalone and consolidated profits signals improving operational performance, which is the more meaningful takeaway for investors. Director changes are routine as Carlyle replaces its board nominee.